Thrivent Financial for Lutherans Sells 302 Shares of Hologic, Inc. (NASDAQ:HOLX)

Thrivent Financial for Lutherans trimmed its position in Hologic, Inc. (NASDAQ:HOLX) by 3.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,548 shares of the medical equipment provider’s stock after selling 302 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Hologic were worth $778,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Wolff Wiese Magana LLC bought a new stake in shares of Hologic during the 3rd quarter valued at $25,000. Innealta Capital LLC bought a new position in Hologic in the 2nd quarter valued at approximately $25,000. Sunbelt Securities Inc. acquired a new stake in shares of Hologic during the 2nd quarter valued at $37,000. Cromwell Holdings LLC boosted its stake in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 416 shares in the last quarter. Finally, Cranbrook Wealth Management LLC bought a new stake in shares of Hologic in the second quarter worth $47,000. 94.73% of the stock is owned by institutional investors.

Hologic Stock Performance

Hologic stock opened at $77.47 on Wednesday. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 1-year low of $67.59 and a 1-year high of $84.67. The firm has a market capitalization of $17.58 billion, a PE ratio of 23.26, a price-to-earnings-growth ratio of 2.49 and a beta of 0.96. The firm’s 50 day simple moving average is $80.13 and its 200 day simple moving average is $78.52.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.89 EPS. As a group, analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. UBS Group boosted their price objective on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. JPMorgan Chase & Co. raised their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Mizuho dropped their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Finally, Leerink Partners reduced their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.